Related Experiment Video
Updated: May 18, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Tranexamic acid-bevacizumab synergy in HHT patients presenting pulmonary arteriovenous malformations
Alexis Lacout1, Pierre Yves Marcy, Mostafa El Hajjam
1Centre d'imagerie Médicale, 47, Boulevard du Pont Rouge, 15000 Aurillac, France. lacout.alexis@wanadoo.fr
Abstract:
Bevacizumab and tranexamic acid have shown efficacy in the treatment of epistaxis and liver involvement of HHT patients. We suggest therapeutic association of bevacizumab and tranexamic acid should be further evaluated for the prevention and treatment of early lung involvement in HHT.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Venous Thrombosis III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Regulation of Angiogenesis and Blood Supply

